1. Japan Stocks

  2. •

    Consumer Defensive

  3. •

    Household & Personal Products
Kobayashi Pharmaceutical Co., Ltd.

Kobayashi Pharmaceutical Co., Ltd.

KBYPF
Kobayashi Pharmaceutical Co., Ltd.US flagOther OTC
34.05
USD
- -
- -
2.53BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1,483.98
1,554.32
1,574.62
1,686.9
1,989.35
2,119.1
2,019.23
1,925.64
1,987.23
2,155.78
2,287.03
2,227.63
2,229.99
1,244.62
Basic EPS, GAAP
148.68
150.28
152.72
165.55
201.31
228.04
244.07
245.7
252.35
259.61
268.16
135.42
49.19
116.18
Free Cash Flow per Basic Share
77.74
124.17
144.37
126.41
242.96
206.32
194.92
253.79
233.4
203.38
63.17
-206.93
155.79
- -
Dividend per Share
40.99
42.99
43.58
47.17
55.11
60.96
68.01
74
80.01
84.4
95.24
100.96
102.97
- -
Book Value per Share
1,384.63
1,491.9
1,610.98
1,732.7
1,906.19
2,066.31
2,258.47
2,437.48
2,611
2,563.92
2,757.43
2,847.63
2,794.38
2,833.08
Tangible Book Value per Share
1,340.46
1,483.89
1,644.34
1,680.49
1,891.02
2,042.49
2,162.12
2,172.23
2,341.64
2,393.51
2,415.55
2,593.47
2,604.73
2,562.63
Basic Weighted Avg Shares
82
82
82
81
79
79
78
78
78
77
76
74
74
74
Sales/Revenue/Turnover
121,532
127,293
128,344
137,211
156,761
167,479
158,340
150,514
155,252
166,258
173,455
165,600
165,742
92,464
Operating Margin (%)
13.91
14.24
13.96
13.31
14.63
15.7
16.21
17.24
16.79
16.04
14.86
15.02
9.01
16.65
Depreciation Expense
2,969
3,096
3,095
3,071
3,519
3,403
4,127
4,106
4,835
5,358
6,057
8,022
8,745
- -
Net Income, GAAP
12,176
12,307
12,448
13,466
15,863
18,023
19,139
19,205
19,715
20,022
20,338
10,067
3,656
8,631
Effective Tax Rate (%)
35.41
37.42
37.93
28.26
29.72
28.77
28.6
27.9
28.66
28.36
26.2
27.61
2.22
25.94
Profit Margin (%)
10.02
9.67
9.7
9.81
10.12
10.76
12.09
12.76
12.7
12.04
11.73
6.08
2.21
9.33
Working Capital
59,876
71,398
80,100
83,866
88,072
96,771
109,279
114,118
131,186
121,083
102,220
98,045
88,683
89,466
LT Debt
163
609
513
618
527
472
682
505
460
531
608
503
359
394
Total Equity
114,870
126,951
139,609
142,023
153,810
166,247
172,657
182,582
195,599
197,899
204,816
213,470
211,008
208,241
Return on Invested Capital (%)
9.6
9.01
8.03
9.03
10.54
11.24
10.39
10.15
9.54
9.45
9.19
8.43
6.77
5.37
Return on Capital (%)
11.12
10.4
9.78
9.86
10.85
11.45
11.19
10.41
9.97
9.94
9.96
4.77
1.75
4.13
Return on Common Equity (%)
11.17
10.45
9.82
9.89
10.9
11.5
11.24
10.45
9.99
9.97
10
4.78
1.74
4.14

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
343
- -
355
LT Borrowings
- -
- -
- -
LT Finance Leases
503
- -
394
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
74
- -
74
Market Capitalization
437,495
417,148
400,736

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
144,468
- -
135,971
Cash, Cash Equivalents & STI
65,745
- -
69,674
Accounts Receivable, Net
49,442
- -
32,973
Inventories
24,163
- -
30,653
Total Current Liabilities
46,423
- -
46,505
Payables & Accruals
- -
- -
- -
ST Debt
343
- -
355
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.26%
2.98%
-1.15%
Free Cash Flow
-60.56%
-137.57%
-175.27%
Net Income, GAAP
-6.22%
-21.68%
-63.68%
Sales/Revenue/Turnover
2.77%
2.03%
0.09%
Total Cash Common Dividend
8.03%
5.81%
1.97%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
36,485
36,651
41,323
51,141
165,600
2025
- -
- -
- -
- -
165,742
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13.13
- -
- -
- -
135.42
2025
- -
- -
- -
- -
49.19
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
100.96
2025
- -
- -
- -
- -
102.97
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Yumi Nakagawa
Full Time Employees
3,615
Sector
Consumer Defensive
Industry
Household & Personal Products
Address
KDX Kobayashi Doshomachi Building Osaka Japan 541-0045
IPO Date
Sep 14, 2015
Website
kobayashi.co.jp
Similar Companies
It'S Hanbul Co., Ltd. (226320.KS)
Kimberly-Clark de México, S. A. B. de C. V. (KIMBERA.MX)
The Estée Lauder Companies Inc. (EL)
Warpaint London PLC (W7L.L)
Zurvita Holdings, Inc. (ZRVT)
Green Bridge Industries, Inc. (GRBG)
Business
Kobayashi Pharmaceutical Co., Ltd. manufactures and sells over-the-counter pharmaceuticals, quasi-drugs, consumer health products, household goods, skincare items and body warmers in Japan and internationally. The company offers a broad range of branded products including Ammeltz topical analgesic; Inochi no Haha women's health medicine; Naishitol or Naicitol Chinese medicine; Sarasaty lingerie soap; Bluelet Decoral or Ekitai Bluelet Okudake toilet bowl cleaners and fresheners; BreathCare oral breath freshener capsules; Netsusama sheet cooling gel sheets; Eyebon eye wash; Eaude Muge medicated acne lotion; Itoyoji dental floss picks; Sawaday toilet air freshener; Dent effervescent denture cleaner; deodorizing air fresheners; lens cleaners; oral hygiene products; health foods; nutritional supplements; cosmetics; hygiene and paper products; and synthetic resin processed items. It also markets skincare and daily necessities through websites and mail order, while engaging in transportation, real estate management, advertising production and asset management activities. Founded in 1886 and headquartered in Osaka, Japan, the company operates primarily in the healthcare, consumer products and personal care segments targeting domestic and select international markets. In recent major developments, Kobayashi Pharmaceutical faces an ongoing crisis from its red yeast rice (beni koji) supplements, including Red Koji Cholesterol Help, which prompted a voluntary recall in March 2024 after reports of acute kidney issues linked to puberulic acid contamination; production of these products ceased in August 2024 amid over 80 suspected deaths, thousands of hospitalizations and widespread product recalls involving partners in Japan and Taiwan; additionally, Chairman Kazumasa Kobayashi and President Akihiro Kobayashi resigned in July 2024 as the firm continues investigations and health consultations.